Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Safety and Efficacy of 3-month Subcutaneous REGN1033 Treatment in Patients With Sarcopenia

Authors not listed

Regeneron Pharmaceuticals · 2013

Abstract

This is a randomized, double-blind, placebo-controlled, multicenter phase 2 study of the safety and efficacy of 3-month subcutaneous (SC) REGN1033 (SAR391786) treatment in patients with sarcopenia.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-30 MST

Cite this

APA
Anonymous. (2013). A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Safety and Efficacy of 3-month Subcutaneous REGN1033 Treatment in Patients With Sarcopenia. <em>Regeneron Pharmaceuticals</em>. https://clinicaltrials.gov/study/NCT01963598
Vancouver
Anonymous. A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Safety and Efficacy of 3-month Subcutaneous REGN1033 Treatment in Patients With Sarcopenia. Regeneron Pharmaceuticals. 2013.
BibTeX
@misc{anon2013ARando, title = {A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Safety and Efficacy of 3-month Subcutaneous REGN1033 Treatment in Patients With Sarcopenia}, author = {Anonymous}, journal = {Regeneron Pharmaceuticals}, year = {2013}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings